DYNAMIC NERVE STIMULATION IN COMBINATION WITH OTHER EATING DISORDER TREATMENT MODALITIES

• US 20080262411A1
• Filed: 06/02/2006
• Published: 10/23/2008
• Est. Priority Date: 06/02/2006
• Status: Abandoned Application

• Current Assignee: Advanced Neuromodulation Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Advanced Neuromodulation Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Dobak, John D.
• Application Number:
  US11/422,019
• Publication Number:
  US 20080262411A1
• Time in Patent Office: Days
• US Class Current: 604/20
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 38/2264 Obesity-gene products, e.g. leptin
• CPC Class Codes: A61K 41/00 Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36017 with leads or electrodes penetrating the skin
• CPC Class Codes: A61N 1/36082 Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
• CPC Class Codes: A61N 1/36085 Eating disorders or obesity
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents

Abstract

A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and/or administering a weight loss drug.

Claims

1. A method of preventing or treating an eating disorder in a mammal comprising:

electrically stimulating a splanchnic nerve of the mammal; and

administering a weight loss composition in a pharmaceutically effective amount to produce weight loss in the mammal.

2. The method of claim 1, wherein the weight loss composition comprises an appetite suppressant.

3. The method of claim 2, wherein the appetite suppressant is one or more selected from the group consisting of a noradrenergic agent, a serotonergic agent, and an adrenergic/serotonergic agent.

4. The method of claim 3, wherein the appetite suppressant is one or more selected from the group consisting of phenylpropanolamine, phentermine, fenfluramine, dexfenfluramine, fluoxetine, sibutramine.

5. The method of claim 1, wherein the weight loss composition comprises a thermogenic agent.

6. The method of claim 5, wherein the thermogenic agent is one or more selected from the group consisting of a sympathomimetic and a selective Beta 3-adrenergic agonist.

7. The method of claim 1, wherein the weight loss composition comprises a digestive inhibitor.

8. The method of claim 7, wherein the digestive inhibitor is a lipase inhibitor.

9. The method of claim 7, wherein the lipase inhibitor is tetrahydrolipostatin.

10. The method of claim 1, wherein the weight loss composition comprises a cannabinoid antagonist.

11. The method of claim 1, wherein the weight loss composition comprises an anatagonist of a hormone or hormone receptor that increases food intake.

12. The method of claim 11, wherein the hormone is one or more selected from the group consisting of Neuropeptide Y, Orexins, and Ghrelin.

13. The method of claim 1, wherein the weight loss composition comprises an agonist of a hormone or hormone receptor that decreases food intake.

14. The method of claim 13, wherein the hormone is one or more selected from the group consisting of Glucagon-like-peptide 1, Cholecystokinin, Peptide YY (3-36), amylin, and melanocortins.

15. The method of claim 1, wherein the weight loss composition comprises one or more selected from leptin, a leptin stimulator, adiponectin, and an adiponectin stimulator.

16. The method of claim 1, wherein the weight loss composition comprises one or more selected from the group consisting of at least one appetite suppressant, at least one digestive inhibitor, at least one cannabinoid antagonist, at least one anatagonist of a hormone or hormone receptor that increases body weight, and at least one agonist of a hormone or hormone receptor that decreases body weight.

17. The method of claim 1, further comprising performing a surgical procedure configured to produce weight loss in the mammal.

18. A method of treating or prevent an eating disorder comprising:

electrically stimulating a splanchnic nerve of a mammal; and

performing a surgical procedure configured to produce weight loss in the mammal.

19. The method of claim 18, wherein the surgical procedure comprises a bypass.

20. The method of claim 19, wherein the surgical procedure comprises one or more selected the group consisting of jejuno-illeo bypass and a roux-en-Y gastric bypass.

21. The method of claim 18, wherein the surgical procedure comprises a gastric restrictive procedure.

22. The method of claim 21, wherein the gastric restrictive procedure comprises one or more selected from the group consisting of gastric banding, adjustable gastric banding, gastric stapling, and vertical banded gastroplasty.

23. The method of claim 18, wherein the surgical procedure comprises a partial biliopancreatic diversion.

24. The method of claim 18, wherein the surgical procedure comprises implanting a gastric displacement device.

25. The method of claim 24, wherein the gastric displacement device is a gastric balloon.

26. A method of preventing or treating an eating disorder comprising:

electrically stimulating a splanchnic nerve in a mammal to reduce a level of serum CRP in the mammal; and

repeating splanchnic nerve stimulation in a manner to maintain a reduced level of CRP.

27. A method of preventing or treating an eating disorder comprising:

electrically stimulating a splanchnic nerve in a mammal to reduce a level of serum CRP in the mammal; and

administering a weight loss drug in a dose configured to produce weight loss in the mammal.

28. The method of claim 27, wherein the step of administering a weight loss drug comprises administering exogenous leptin to the mammal.

29. The method of claim 27, wherein the administering of the weight loss drug is configured to maintain a reduced level of serum CRP.